CN115557958A - A method for preparing biotin intermediate optically active lactone - Google Patents
A method for preparing biotin intermediate optically active lactone Download PDFInfo
- Publication number
- CN115557958A CN115557958A CN202110753405.2A CN202110753405A CN115557958A CN 115557958 A CN115557958 A CN 115557958A CN 202110753405 A CN202110753405 A CN 202110753405A CN 115557958 A CN115557958 A CN 115557958A
- Authority
- CN
- China
- Prior art keywords
- imide
- sodium borohydride
- biotin intermediate
- reduced
- optically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 36
- 150000002596 lactones Chemical class 0.000 title claims abstract description 34
- 229960002685 biotin Drugs 0.000 title claims abstract description 31
- 235000020958 biotin Nutrition 0.000 title claims abstract description 30
- 239000011616 biotin Substances 0.000 title claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 59
- 150000003949 imides Chemical class 0.000 claims abstract description 43
- 229910000033 sodium borohydride Inorganic materials 0.000 claims abstract description 20
- 239000012279 sodium borohydride Substances 0.000 claims abstract description 20
- 150000001412 amines Chemical class 0.000 claims abstract description 12
- 238000000746 purification Methods 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 238000001953 recrystallisation Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 abstract description 6
- 150000001414 amino alcohols Chemical class 0.000 abstract description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 abstract description 4
- 238000007670 refining Methods 0.000 abstract description 4
- 239000012535 impurity Substances 0.000 abstract description 3
- 238000007142 ring opening reaction Methods 0.000 abstract description 3
- 238000002425 crystallisation Methods 0.000 abstract description 2
- 230000008025 crystallization Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 23
- 238000006722 reduction reaction Methods 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- OROGUZVNAFJPHA-UHFFFAOYSA-N 3-hydroxy-2,4-dimethyl-2H-thiophen-5-one Chemical compound CC1SC(=O)C(C)=C1O OROGUZVNAFJPHA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940068840 d-biotin Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000010921 in-depth analysis Methods 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
技术领域technical field
本发明涉及维生素中间体领域,具体地说是一种制备生物素中间体光学活性内酯的方法。The invention relates to the field of vitamin intermediates, in particular to a method for preparing optically active lactones of biotin intermediates.
背景技术Background technique
(+)-生物素(Biotin)又称维生素H或辅酶R,化学名为(3aS,4S,6aR)-六氢-2-氧代-1H-噻吩并[3,4-d]咪唑-4-戊酸,广布于动物及植物组织,已从肝提取物和蛋黄中分离得到,是多种羧化酶辅基的成分,是动植物生长发育所必需的物质。(+)-Biotin, also known as vitamin H or coenzyme R, chemically named (3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4 -Valeric acid, widely distributed in animal and plant tissues, has been isolated from liver extract and egg yolk, is a component of a variety of carboxylase prosthetic groups, and is a necessary substance for the growth and development of animals and plants.
自1944年Merck公司首次合成d-生物素后,现已有40多种生物素的化学全合成法。起始原料有L-半胱氨酸、L-半氨酸、富马酸、d-葡萄糖、d-阿拉伯糖、庚二酸等,其中最为经典的是Roche公司的Goldberg-Sterbach工艺,首次实现了生物素的工业化生产,现在工业化的工艺大部分来自于该工艺的改进。该路线的一个关键中间体是光活性内酯(Ⅳ),其与硫代乙酸钾,在DMF中反应,能保持构型,并以较高收率得到光活性硫代内酯(Ⅴ)。利用光活性硫代内酯,可以经几步反应直接合成d-生物素,合成路线如下:Since the first synthesis of d-biotin by Merck in 1944, there are now more than 40 chemical total synthesis methods of biotin. The starting materials include L-cysteine, L-cysteine, fumaric acid, d-glucose, d-arabinose, pimelic acid, etc. Among them, the most classic one is the Goldberg-Sterbach process of Roche Company, which realizes for the first time The industrialized production of biotin has been eliminated, and most of the industrialized processes now come from the improvement of the process. A key intermediate of this route is photoactive lactone (Ⅳ), which reacts with potassium thioacetate in DMF to maintain configuration and obtain photoactive thiolactone (Ⅴ) in higher yield. Using photoactive thiolactone, d-biotin can be directly synthesized through several steps, and the synthetic route is as follows:
因此,作为关键中间体,光学活性内酯(Ⅳ)的合成显得极其重要。Therefore, as a key intermediate, the synthesis of optically active lactone (Ⅳ) is extremely important.
1975年,Sumitomo公司发明了一种光学活性内酯(Ⅳ)的不对称合成方法:内消旋二酸先与(S,S)-(+)-苏式-1-(对硝基苯基)-2-氨基-1,3-丙二醇(抗生素氯霉素的副产物)反应得到酰亚胺(Ⅱ),经NaBH4还原、开环得胺醇(ⅢA),再经重结晶除去其光学副产物(ⅢB);然后胺醇(ⅢA)酸水解得到需要的光学活性内酯(Ⅳ),经重结晶后收率为65%,e.e值达到98%。其中控制内酯光学纯度的关键是胺醇(ⅢA)的纯度,合成路线如下:In 1975, Sumitomo Company invented an asymmetric synthesis method of optically active lactone (Ⅳ): meso diacid was first combined with (S, S)-(+)-threo-1-(p-nitrophenyl )-2-amino-1,3-propanediol (the by-product of the antibiotic chloramphenicol) was reacted to obtain imide (Ⅱ), which was reduced by NaBH 4 and ring-opened to obtain amine alcohol (ⅢA), and then recrystallized to remove its optical The by-product (ⅢB); then the amino alcohol (ⅢA) is acid-hydrolyzed to obtain the desired optically active lactone (Ⅳ), and the yield after recrystallization is 65%, and the ee value reaches 98%. Wherein the key to controlling the optical purity of the lactone is the purity of the aminoalcohol (ⅢA), and the synthetic route is as follows:
酰亚胺(Ⅱ)的两个羰基由于具有不同的化学环境而被不对称的还原,在产生目标产物(ⅢA)的同时,会不可避免的产生少量的另一非对映异构体(ⅢB)。如果不经分离,非对映异构体(ⅢB)水解得到的光学异构体杂质(ⅣB)会一直带入到最终产品,影响产品生物素的含量;如果进行分离精制,就会使收率大幅降低。The two carbonyl groups of imide (II) are asymmetrically reduced due to different chemical environments, and while producing the target product (IIIA), a small amount of another diastereoisomer (IIIB ). If not separated, the optical isomer impurity (IVB) obtained by the hydrolysis of the diastereoisomer (ⅢB) will always be brought into the final product, affecting the content of product biotin; if separated and refined, the yield will be reduced. significantly reduce.
发明内容Contents of the invention
本发明的目的是提供一种制备生物素中间体光学活性内酯的方法,所述方法包括如下步骤:The object of the present invention is to provide a kind of method for preparing biotin intermediate optically active lactone, described method comprises the steps:
1)将如式(II)所示的生物素中间体酰亚胺用硼氢化钠还原得到式(I)所示的酰亚胺还原物,其中,硼氢化钠为批量添加;1) Reducing the biotin intermediate imide shown in formula (II) with sodium borohydride to obtain the imide reduction product shown in formula (I), wherein sodium borohydride is added in batches;
2)将步骤1)中得到的酰亚胺还原物进行纯化;2) Purifying the reduced imide obtained in step 1);
3)将步骤2)纯化后的酰亚胺还原物再用硼氢化钠还原开环,以得到如式(III)所示的生物素中间体胺醇,其中,硼氢化钠为批量添加;3) The purified imide reduction product in step 2) is reduced and opened with sodium borohydride to obtain the biotin intermediate amine alcohol shown in formula (III), wherein sodium borohydride is added in batches;
4)将所述生物素中间体胺醇用酸水解后,以得到如式(IV)所示的生物素中间体光学活性内酯;4) hydrolyzing the biotin intermediate amine alcohol with acid to obtain the biotin intermediate optically active lactone shown in formula (IV);
其中R*为手性胺,Bn为苄基。Wherein R* is chiral amine, Bn is benzyl.
本发明对酰亚胺(Ⅱ,结构式如下)的不对称还原反应进行深入分析后,认为NaBH4对酰亚胺的4位和6位羰基的选择性还原主要是由于空间位阻的影响。位于6位的羰基由于空间位阻小,优先被还原为醇。After an in-depth analysis of the asymmetric reduction reaction of the imide (II, the following structural formula), the present invention believes that the selective reduction of the 4- and 6-carbonyl groups of the imide by NaBH 4 is mainly due to the influence of steric hindrance. The carbonyl at position 6 is preferentially reduced to alcohol due to the small steric hindrance.
式(Ⅰ)所示的酰亚胺还原物,其化学名为(3aS,6aR)-1,3-二苄基-5-[(1S,2S)-(+)-苏式-1’-羟甲基-2’-对硝基苯基-2’-羟基-乙基]-六氢-1H-吡咯并[3,4-d]咪唑-6-羟基-2,4-二酮:The imide reduction product represented by formula (I), its chemical name is (3aS, 6aR)-1,3-dibenzyl-5-[(1S,2S)-(+)-threo-1'- Hydroxymethyl-2'-p-nitrophenyl-2'-hydroxy-ethyl]-hexahydro-1H-pyrrolo[3,4-d]imidazole-6-hydroxy-2,4-dione:
其中Bn为苄基。Wherein Bn is benzyl.
在本发明的方法的优选技术方案中,优选地,R*为右胺,(1S,2S)-(+)-苏式-1-(对硝基苯基)-2-氨基-1,3-丙二醇。In the preferred technical scheme of the method of the present invention, preferably, R* is the right amine, (1S,2S)-(+)-threo-1-(p-nitrophenyl)-2-amino-1,3 - Propylene glycol.
在本发明的方法的优选技术方案中,优选地,步骤1)中,硼氢化钠用量与所述生物素中间体酰亚胺用量的摩尔比为0.3-0.5:1,所述含水乙醇溶剂体积用量与所述生物素中间体酰亚胺重量用量的比为3-6:1,在含水乙醇溶剂中,在-15~0℃下反应。In the preferred technical scheme of the method of the present invention, preferably, in step 1), the molar ratio of the amount of sodium borohydride to the amount of the biotin intermediate imide is 0.3-0.5:1, and the volume of the aqueous ethanol solvent The ratio of the dosage to the weight dosage of the biotin intermediate imide is 3-6:1, and the reaction is carried out in a water-containing ethanol solvent at -15-0°C.
在本发明的方法的优选技术方案中,优选地,步骤2)中,所述酰亚胺还原物的纯化为重结晶纯化。In a preferred technical solution of the method of the present invention, preferably, in step 2), the purification of the reduced imide is recrystallization purification.
在本发明的方法的优选技术方案中,优选地,步骤3)中,硼氢化钠用量与所述纯化后的酰亚胺还原物用量的摩尔比为2.0-2.2:1,所述含水乙醇体积用量与所述酰亚胺还原物重量用量的比为3-6:1,在含水乙醇溶剂中,在5~10℃下反应。In the preferred technical scheme of the method of the present invention, preferably, in step 3), the molar ratio of the amount of sodium borohydride to the amount of the purified imide reduced product is 2.0-2.2:1, and the volume of the aqueous ethanol The ratio of the amount used to the weight amount of the imide reducing product is 3-6:1, and the reaction is carried out in a water-containing ethanol solvent at 5-10°C.
在本发明的方法的优选技术方案中,优选地,步骤3)中,所述生物素中间体胺醇还可以进一步纯化。In the preferred technical solution of the method of the present invention, preferably, in step 3), the biotin intermediate amine alcohol can be further purified.
在本发明的方法的优选技术方案中,优选地,所述水解的温度为90-100℃,所述酸选自乙酸、盐酸、硫酸中的一种。In a preferred technical solution of the method of the present invention, preferably, the hydrolysis temperature is 90-100° C., and the acid is selected from one of acetic acid, hydrochloric acid, and sulfuric acid.
在本发明的方法的优选技术方案中,优选地,步骤1)和步骤3)中,所述含水乙醇溶剂为95%乙醇水溶液。In the preferred technical solution of the method of the present invention, preferably, in step 1) and step 3), the aqueous ethanol solvent is 95% ethanol aqueous solution.
在本发明的方法的优选技术方案中,优选地,所述重结晶的溶剂为甲醇、乙醇或异丙醇。In a preferred technical solution of the method of the present invention, preferably, the solvent for the recrystallization is methanol, ethanol or isopropanol.
在本发明的方法的优选技术方案中,优选地,步骤4)中,水解后,进行薄层检测,完毕后,停止加热,冷却至室温,用碱液中和至中性;然后用有机溶剂萃取,水洗两次后,干燥,减压回收溶剂后,重结晶得到白色晶体状粉末内酯(IV);所述碱液选自氢氧化钠、碳酸钠、碳酸氢钠的水溶液中的一种;所述有机溶剂选自甲苯、正己烷、环己烷、乙醚、二氯甲烷中的一种。In the preferred technical solution of the method of the present invention, preferably, in step 4), after hydrolysis, thin-layer detection is carried out, and after completion, stop heating, cool to room temperature, and neutralize to neutrality with lye; then use organic solvent Extraction, washing with water twice, drying, recovering the solvent under reduced pressure, recrystallization to obtain white crystalline powder lactone (IV); the lye is selected from one of the aqueous solutions of sodium hydroxide, sodium carbonate and sodium bicarbonate ; The organic solvent is selected from one of toluene, normal hexane, hexanaphthene, ether, and methylene chloride.
本发明通过对酰亚胺进行还原,得到选择性还原产物,并通过结晶精制去除手性杂质,得到纯的还原物,该还原产物继续还原后得到胺醇,可不经分离提纯直接进行水解得到光学纯度合格的光学活性内酯(Ⅳ),总收率提高,操作简化,废料减少,极具工业价值。In the present invention, the selective reduction product is obtained by reducing the imide, and the chiral impurities are removed by crystallization and purification to obtain a pure reduction product, which can be further reduced to obtain an amino alcohol, which can be directly hydrolyzed without separation and purification to obtain an optical The optically active lactone (Ⅳ) with qualified purity has improved total yield, simplified operation and reduced waste, and has great industrial value.
附图说明Description of drawings
图1A为酰亚胺还原产物(I)的1H-NMR谱;Fig. 1A is the 1 H-NMR spectrum of imide reduction product (I);
图1B为酰亚胺还原产物(I)的13C-NMR谱;Fig. 1B is the 13 C-NMR spectrum of imide reduction product (I);
图2A为生物素中间体光学活性内酯(Ⅳ)的红外谱图;Fig. 2A is the infrared spectrogram of biotin intermediate optically active lactone (IV);
图2B为生物素中间体光学活性内酯(Ⅳ)的1H-NMR谱;Figure 2B is the 1 H-NMR spectrum of the biotin intermediate optically active lactone (IV);
图2C为生物素中间体光学活性内酯(Ⅳ)的13C-NMR谱;Figure 2C is the 13 C-NMR spectrum of the biotin intermediate optically active lactone (IV);
图2D为生物素中间体光学活性内酯(Ⅳ)的DEPT135谱;Figure 2D is the DEPT135 spectrum of the biotin intermediate optically active lactone (Ⅳ);
图3为由浙江大学分析测试中心对酰亚胺还原产物(I)进行晶体结构测定的立体结构图。Fig. 3 is a three-dimensional structure diagram of the crystal structure determination of the imide reduction product (I) by the Analysis and Testing Center of Zhejiang University.
具体实施方式detailed description
现结合所附较佳实施例详细说明如下,所附的较佳实施例仅用于说明本发明的技术方案,并非限定本发明。The detailed description is as follows with reference to the attached preferred embodiments, and the attached preferred embodiments are only used to illustrate the technical solutions of the present invention, not to limit the present invention.
在本发明的各个实施例中所使用的分析仪器与设备为:核磁共振仪,AVANCE DMXⅡⅠ400M(TMS内标,Bruker公司);红外光谱仪,NICOLET 360FT-IR。The analytical instruments and equipment used in the various embodiments of the present invention are: nuclear magnetic resonance instrument, AVANCE DMX Ⅱ Ⅰ 400M (TMS internal standard, Bruker Company); infrared spectrometer, NICOLET 360FT-IR.
实施例1:酰亚胺还原物(Ⅰ)的制备Embodiment 1: the preparation of imide reduction product (I)
将21.2g酰亚胺(0.04mol)放入三口烧瓶中,加入溶剂95%乙醇水溶液80ml,在-10℃时分批加入0.65g硼氢化钠(0.017mol),约1小时加完,维持-15~0℃反应约1小时,薄层色谱检测反应完全,用乙酸中和至中性,蒸干溶剂后,加入异丙醇50毫升,加热溶解,冷却到5℃结晶,析出大量白色固体,抽滤,干燥得产物18.9g,摩尔收率88.7%,mp96~97℃。Put 21.2g of imide (0.04mol) into a three-necked flask, add 80ml of solvent 95% ethanol aqueous solution, and add 0.65g of sodium borohydride (0.017mol) in batches at -10°C, and add it in about 1 hour. React at 15-0°C for about 1 hour. Thin-layer chromatography detects that the reaction is complete. Neutralize to neutral with acetic acid. After evaporating the solvent, add 50 ml of isopropanol, heat to dissolve, cool to 5°C to crystallize, and precipitate a large amount of white solid. Suction filtration and drying yielded 18.9 g of the product, with a molar yield of 88.7%, and mp of 96-97°C.
1H NMR(400MHz,DMSO)δ8.181(d,J=8.4Hz,2H),7.621(d,J=8.4Hz,2H),7.179–7.380(m,10H),6.675(d,J=6.0Hz,1H),6.159–6.171(m,1H),5.209–5.236(m,1H),5.063–5.090(m,1H),4.815–4.891(m,2H),4.662(d,J=15.2Hz,1H),4.164(d,J=15.2Hz,1H),3.906–4.027(m,3H),3.617–3.677(m,2H),3.522–3.577(m,1H),如图1A所示。 1 H NMR (400MHz, DMSO) δ8.181 (d, J = 8.4Hz, 2H), 7.621 (d, J = 8.4Hz, 2H), 7.179–7.380 (m, 10H), 6.675 (d, J = 6.0 Hz,1H),6.159–6.171(m,1H),5.209–5.236(m,1H),5.063–5.090(m,1H),4.815–4.891(m,2H),4.662(d,J=15.2Hz, 1H), 4.164(d, J=15.2Hz, 1H), 3.906–4.027(m, 3H), 3.617–3.677(m, 2H), 3.522–3.577(m, 1H), as shown in Fig. 1A.
13C NMR(101MHz,DMSO)δ170.40,159.01,150.40,146.66,137.39,136.91,128.61,128.49,127.98,127.92,127.82,127.35,127.25,123.07,79.21,70.15,60.23,58.37,55.17,52.13,46.38,45.35,如图1B所示。 13 C NMR(101MHz,DMSO)δ170.40,159.01,150.40,146.66,137.39,136.91,128.61,128.49,127.98,127.92,127.82,127.35,127.25,123.07,79.21,70.15,60.23,58.37,55.17,52.13,46.38, 45.35, as shown in Figure 1B.
实施例2:酰亚胺还原物(Ⅰ)继续还原、水解制备内酯Example 2: Continued reduction and hydrolysis of imide reducing product (I) to prepare lactone
250ml的三口烧瓶中加入95%的含水乙醇80ml,在5℃的冷浴中搅拌,加入10.6g(0.020mol)上例(实施例1)制备的还原物,搅拌几分钟后开始批加1.6g(0.042mol)硼氢化钠,在半小时左右加完,开始的时候还原物不溶,当批加完时溶液变澄清,继续保温搅拌48小时左右,薄层检测反应完成后,用醋酸中和至中性,蒸掉溶剂,得粗品。向瓶中加入20%硫酸水溶液59g(0.12mol),在90-100℃下磁力搅拌回流4h,薄层检测反应完后,停止加热,冷却至室温,用稀碱液(10%的氢氧化钠水溶液)中和至中性,然后用150ml的二氯甲烷萃取三次,合并有机层,水洗两次后,用2g无水硫酸钠干燥,减压回收溶剂后,用95%乙醇水溶液重结晶。得白色固体粉末5.8g,摩尔收率90.0%,mp116~117℃,比旋光度[α]D 20=+59.4°,e.e值98.9%。Add 80ml of 95% aqueous ethanol to a 250ml three-necked flask, stir in a cold bath at 5°C, add 10.6g (0.020mol) of the reduced product prepared in the previous example (Example 1), and start adding 1.6g in batches after stirring for a few minutes (0.042mol) sodium borohydride, added in about half an hour, the reduction was insoluble at the beginning, when the batch was added, the solution became clear, continued to insulate and stir for about 48 hours, after the TLC detection reaction was completed, neutralized with acetic acid until Neutral, distill off the solvent to obtain the crude product. Add 59g (0.12mol) of 20% sulfuric acid aqueous solution to the bottle, magnetically stir and reflux at 90-100°C for 4h, after the TLC detection reaction is completed, stop heating, cool to room temperature, and use dilute lye (10% sodium hydroxide aqueous solution) neutralized to neutral, then extracted three times with 150ml of dichloromethane, combined the organic layers, washed twice with water, dried with 2g of anhydrous sodium sulfate, recovered the solvent under reduced pressure, and recrystallized with 95% aqueous ethanol. 5.8 g of white solid powder was obtained, the molar yield was 90.0%, the mp was 116-117°C, the specific rotation [α] D 20 =+59.4°, and the ee value was 98.9%.
上述2步反应,酰亚胺先还原到还原物,精制、还原开环、水解、重结晶后,得到符合含量要求的产物内酯,2步摩尔总收率79.8%。In the above two-step reaction, the imide is first reduced to the reduced product, and after refining, reduction ring-opening, hydrolysis and recrystallization, the product lactone meeting the content requirement is obtained, and the total molar yield of the two steps is 79.8%.
结构确认:Confirmation of structure:
IR:3033.75(Ar-H),1769.88(C=O,酯),1700.57(C=O,酮),1443.71(C=C,苯),1211.33(C-O,酯),697.62(δAr-H),如图2A所示。IR: 3033.75 (Ar-H), 1769.88 (C=O, ester), 1700.57 (C=O, ketone), 1443.71 (C=C, benzene), 1211.33 (C-O, ester), 697.62 (δAr-H ), as shown in Figure 2A.
1HNMR(CDCl3):7.252~7.400(m,10H,苯环H),5.062(d,1H,J=14.8HZ,C7H),4.646(d,1H,J=15.2HZ,C8H),4.389(d,1H,J=14.4HZ,C7H),4.360(d,1H,J=14.8HZ,C8 H),4.162(s,2H,C6 H),4.1066~4.133(C3aH),3.925(d,1H,J=8.8HZ,C6aH),如图2B所示。 1 HNMR (CDCl 3 ): 7.252~7.400 (m, 10H, benzene ring H), 5.062 (d, 1H, J=14.8H Z , C7H), 4.646 (d, 1H, J=15.2H Z , C8H), ( _ d, 1H, J=8.8H Z , C6aH), as shown in Fig. 2B.
13CNMR(CDCl3):172.76(C4),158.12(C2),135.94(C10),135.83(C9),127.80~128.94(除9、10外的苯环C),70.04(C6),54.33(C6a),52.39(C3a),46.83(C7),45.15(C8),如图2C所示。 13 CNMR (CDCl 3 ): 172.76 (C4), 158.12 (C2), 135.94 (C10), 135.83 (C9), 127.80~128.94 (benzene ring C except 9, 10), 70.04 (C6), 54.33 (C6a ), 52.39(C3a), 46.83(C7), 45.15(C8), as shown in Figure 2C.
DEPT(θ=135°):127.80~128.94,70.03(D),54.33,52.39,46.827(D),45.149(D),如图2D所示。DEPT (θ=135°): 127.80~128.94, 70.03(D), 54.33, 52.39, 46.827(D), 45.149(D), as shown in Fig. 2D.
单晶的培养:将上述得到的内酯晶体粉末少许放在小瓶中,用乙醇溶解,用滤纸封口,放置五周后析出无色透明晶体,由浙江大学分析测试中心进行晶体结构测定,测定的立体结构如图3所示。Cultivation of single crystals: Put a little of the lactone crystal powder obtained above in a vial, dissolve it with ethanol, seal it with filter paper, and leave it for five weeks to precipitate colorless transparent crystals. The crystal structure was determined by the Analysis and Testing Center of Zhejiang University. The three-dimensional structure is shown in Figure 3.
实施例3:酰亚胺还原物(Ⅰ)继续还原、水解制备内酯Example 3: Continued reduction and hydrolysis of imide reducing product (I) to prepare lactone
按上例(实施例2)方法将实施例1制备的酰亚胺还原物(I)继续还原开环得到胺醇(III)粗品。用异丙醇50ml重结晶,得白色固体10.1g。向瓶中加入37%盐酸12g(0.12mol),磁力搅拌回流4h,薄层检测反应完后,停止加热,冷却至室温,用稀碱液(10%的氢氧化钠水溶液)中和至中性,然后用150ml的二氯甲烷萃取三次,合并有机层,水洗两次后,用2g无水硫酸钠干燥,减压回收溶剂后,用95%乙醇重结晶。得白色固体粉末5.5g,收率85.3%,mp116~117℃,比旋光度[α]D 20=+60.0°,e.e值100%。According to the method of the above example (Example 2), the imide reduction product (I) prepared in Example 1 was further reduced and ring-opened to obtain the crude product of aminoalcohol (III). Recrystallize with 50ml of isopropanol to obtain 10.1g of white solid. Add 12g (0.12mol) of 37% hydrochloric acid to the bottle, magnetically stir and reflux for 4 hours, stop heating after the TLC reaction is completed, cool to room temperature, neutralize with dilute lye (10% sodium hydroxide aqueous solution) to neutral , and then extracted three times with 150ml of dichloromethane, combined the organic layers, washed twice with water, dried with 2g of anhydrous sodium sulfate, recovered the solvent under reduced pressure, and recrystallized with 95% ethanol. 5.5 g of white solid powder was obtained, yield 85.3%, mp 116-117°C, specific rotation [α] D 20 =+60.0°,
实施例1及实施例3,酰亚胺先还原到还原物,精制、还原开环、精制、水解、重结晶后,得到符合含量要求的产物内酯,2步摩尔总收率75.7%。结构确认:In Example 1 and Example 3, the imide was first reduced to the reduced product, and after refining, reducing ring opening, refining, hydrolysis, and recrystallization, the product lactone meeting the content requirements was obtained, and the total molar yield in 2 steps was 75.7%. Confirmation of structure:
IR:3033.75(Ar-H),1769.88(C=O,酯),1700.57(C=O,酮),1443.71(C=C,苯),1211.33(C-O,酯),697.62(δAr-H),如图2A所示。IR: 3033.75 (Ar-H), 1769.88 (C=O, ester), 1700.57 (C=O, ketone), 1443.71 (C=C, benzene), 1211.33 (C-O, ester), 697.62 (δAr-H ), as shown in Figure 2A.
1HNMR(CDCl3):7.252~7.400(m,10H,苯环H),5.062(d,1H,J=14.8HZ,C7H),4.646(d,1H,J=15.2HZ,C8H),4.389(d,1H,J=14.4HZ,C7H),4.360(d,1H,J=14.8HZ,C8 H),4.162(s,2H,C6 H),4.1066~4.133(C3aH),3.925(d,1H,J=8.8HZ,C6aH),如图2B所示。 1 HNMR (CDCl 3 ): 7.252~7.400 (m, 10H, benzene ring H), 5.062 (d, 1H, J=14.8H Z , C7H), 4.646 (d, 1H, J=15.2H Z , C8H), ( _ d, 1H, J=8.8H Z , C6aH), as shown in Fig. 2B.
13CNMR(CDCl3):172.76(C4),158.12(C2),135.94(C10),135.83(C9),127.80~128.94(除9、10外的苯环C),70.04(C6),54.33(C6a),52.39(C3a),46.83(C7),45.15(C8),如图2C所示。 13 CNMR (CDCl 3 ): 172.76 (C4), 158.12 (C2), 135.94 (C10), 135.83 (C9), 127.80~128.94 (benzene ring C except 9, 10), 70.04 (C6), 54.33 (C6a ), 52.39 (C3a), 46.83 (C7), 45.15 (C8), as shown in Figure 2C.
DEPT(θ=135°):127.80~128.94,70.03(D),54.33,52.39,46.827(D),45.149(D),如图2D所示。DEPT (θ=135°): 127.80~128.94, 70.03(D), 54.33, 52.39, 46.827(D), 45.149(D), as shown in Fig. 2D.
单晶的培养:将上述得到的内酯晶体粉末少许放在小瓶中,用乙醇溶解,用滤纸封口,放置五周后析出无色透明晶体,由浙江大学分析测试中心进行晶体结构测定,测定的立体结构如图3所示。Cultivation of single crystals: Put a little of the lactone crystal powder obtained above in a vial, dissolve it with ethanol, seal it with filter paper, and leave it for five weeks to precipitate colorless transparent crystals. The crystal structure was determined by the Analysis and Testing Center of Zhejiang University. The three-dimensional structure is shown in Figure 3.
对比实施例1:酰亚胺还原直接水解制备内酯Comparative Example 1: Preparation of Lactone by Direct Hydrolysis of Imide Reduction
250ml的三口烧瓶中加95%的乙醇水溶液100ml,在-10℃的冷浴中搅拌,加入21.2g(0.04mol)酰亚胺,搅拌几分钟后开始批加3.8g(0.10mol)硼氢化钠,在半小时左右加完,薄层跟踪反应进行。将反应液移至室温,磁力搅拌48小时,薄层检测反应完后,醋酸中和至中性,减压蒸掉溶剂,所得固体加入20%硫酸98g(0.2mol),磁力搅拌回流4h,薄层检测反应完后,停止加热,让它冷却至室温,用稀碱液中和至中性,然后用150ml的二氯甲烷萃取三次,合并有机层,水洗两次后,用无水硫酸钠干燥,减压回收溶剂后,用95%乙醇重结晶,得白色晶体状粉末10.9g,总收率84.6%,mp116~118℃,比旋光度[α]D 20=+50.2°,e.e值83.7%。其光学纯度不符合要求。Add 100ml of 95% ethanol aqueous solution to a 250ml three-neck flask, stir in a cold bath at -10°C, add 21.2g (0.04mol) of imide, stir for a few minutes, then add 3.8g (0.10mol) of sodium borohydride in batches , The addition was completed in about half an hour, and the TLC reaction proceeded. The reaction solution was moved to room temperature, and stirred magnetically for 48 hours. After the reaction was detected by TLC, the acetic acid was neutralized to neutral, and the solvent was evaporated under reduced pressure. The obtained solid was added with 20% sulfuric acid 98g (0.2mol), and magnetically stirred and refluxed for 4h. After the layer detection reaction, stop heating, let it cool to room temperature, neutralize to neutral with dilute lye, then extract three times with 150ml of dichloromethane, combine the organic layers, wash twice with water, and dry with anhydrous sodium sulfate , after recovering the solvent under reduced pressure, recrystallize with 95% ethanol to obtain 10.9g of white crystalline powder, the total yield is 84.6%, mp116~118°C, specific rotation [α] D 20 =+50.2°, ee value 83.7% . Its optical purity does not meet the requirements.
其核磁数据与实施例2一致。Its nuclear magnetic data is consistent with
对比实施例2:酰亚胺还原到胺醇,胺醇重结晶后水解制备内酯Comparative Example 2: Reduction of imide to amino alcohol, hydrolysis of amino alcohol to prepare lactone after recrystallization
250ml的三口烧瓶中加入184ml乙醇和16ml水,在-10℃的冷浴中搅拌,加入42.4g(0.08mol)酰亚胺,搅拌几分钟后开始批加7.6g(0.21mol)硼氢化钠,在半小时左右加完,薄层跟踪反应进行。将反应液移至室温,磁力搅拌48小时,薄层检测反应完后,醋酸中和至中性,蒸干溶剂后用异丙醇50ml重结晶,得白色固体26.2g,按上述方法水解,95%乙醇水溶液重结晶,得白色晶体状粉末15.0g,总收率58.0%,mp116~117℃,比旋光度[α]D 20=+60.0°,e.e值100%。Add 184ml of ethanol and 16ml of water into a 250ml three-neck flask, stir in a cold bath at -10°C, add 42.4g (0.08mol) of imide, and start adding 7.6g (0.21mol) of sodium borohydride in batches after stirring for a few minutes. The addition was completed in about half an hour, and the TLC reaction proceeded. The reaction solution was moved to room temperature, and stirred by magnetic force for 48 hours. After the reaction was detected by TLC, the acetic acid was neutralized to neutrality. After the solvent was evaporated, 50ml of isopropanol was used to recrystallize to obtain 26.2g of white solid, which was hydrolyzed according to the above method, 95 % ethanol aqueous solution recrystallized to obtain 15.0 g of white crystalline powder, total yield 58.0%, mp 116-117°C, specific rotation [α] D 20 =+60.0°,
其核磁数据与实施例2一致。Its nuclear magnetic data is consistent with
本发明的方法与对比例1和对比例2的方法比较后,可以得出结论:本发明方法既能得到含量符合要求的产物,又能保证较高收率,极具工业价值。After the method of the present invention is compared with the methods of Comparative Example 1 and Comparative Example 2, it can be concluded that the method of the present invention can not only obtain the product whose content meets the requirements, but also ensure a higher yield, which is of great industrial value.
需要声明的是,上述发明内容及具体实施方式意在证明本发明所提供技术方案的实际应用,不应解释为对本发明保护范围的限定。It should be declared that the above summary of the invention and specific implementation methods are intended to prove the practical application of the technical solutions provided by the present invention, and should not be interpreted as limiting the protection scope of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110753405.2A CN115557958B (en) | 2021-07-02 | 2021-07-02 | Method for preparing biotin intermediate optical activity lactone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110753405.2A CN115557958B (en) | 2021-07-02 | 2021-07-02 | Method for preparing biotin intermediate optical activity lactone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115557958A true CN115557958A (en) | 2023-01-03 |
| CN115557958B CN115557958B (en) | 2024-05-28 |
Family
ID=84736801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110753405.2A Active CN115557958B (en) | 2021-07-02 | 2021-07-02 | Method for preparing biotin intermediate optical activity lactone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115557958B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3876656A (en) * | 1972-06-22 | 1975-04-08 | Sumitomo Chemical Co | Method for synthesis of optically active lactones |
| CN101973996A (en) * | 2010-09-30 | 2011-02-16 | 绍兴文理学院 | Imide biotin intermediate monoester and preparation method and use thereof |
| CN109563102A (en) * | 2016-08-04 | 2019-04-02 | 株式会社德山 | Production method of biotin intermediate, and production method of biotin |
-
2021
- 2021-07-02 CN CN202110753405.2A patent/CN115557958B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3876656A (en) * | 1972-06-22 | 1975-04-08 | Sumitomo Chemical Co | Method for synthesis of optically active lactones |
| CN101973996A (en) * | 2010-09-30 | 2011-02-16 | 绍兴文理学院 | Imide biotin intermediate monoester and preparation method and use thereof |
| CN109563102A (en) * | 2016-08-04 | 2019-04-02 | 株式会社德山 | Production method of biotin intermediate, and production method of biotin |
Non-Patent Citations (1)
| Title |
|---|
| 韩卫华,等: "生物素中间体内酯合成进展", 化学通报, pages 566 - 573 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115557958B (en) | 2024-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1560819B1 (en) | Cannabinoid crystalline derivatives and process of cannabinoid purification | |
| CN114805314B (en) | Synthesis method of Entecavir | |
| CN101973996B (en) | Imide biotin intermediate monoester and preparation method and use thereof | |
| CN115557958B (en) | Method for preparing biotin intermediate optical activity lactone | |
| KR960008664B1 (en) | Process for producing 2,6-dichlorodiphenylaminoacetic acid derivatives | |
| KR950011419B1 (en) | Process for preparing 6,7-discyl-7-deacetyl forsrolin derivati | |
| CN105820102A (en) | Oxiracetam synthesis technology | |
| CN101012192A (en) | Method of preparing zofenopril calcium | |
| CN111635358B (en) | Preparation method of hydroxychloroquine | |
| KR100699457B1 (en) | Method for preparing dibenzothione derivatives and intermediates thereof | |
| JPS60152469A (en) | Preparation of cis-diester derivative | |
| KR910002282B1 (en) | Process for preparing indene acetic acid derivative | |
| AU2004326111A1 (en) | Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI | |
| KR890002253B1 (en) | Process for preparing thiazole compound | |
| CA2770448C (en) | Cannabinoid esters | |
| KR100503267B1 (en) | Method for the preparation of 2-acetyloxy-4-trifluoromethyl benzoic acid | |
| KR870001044B1 (en) | Process for preparing dihydro-1,4-oxathiins | |
| KR900004908B1 (en) | Alpha-(hydroxy) -1,3-oxathiolune derivatives and their preparation | |
| CN121045287A (en) | Synthesis and application of a phenylpropanoid glycoside compound, coniferin B | |
| KR100327553B1 (en) | Method for manufacturing 4-hydroxycoumarin and its analogs | |
| SU904295A1 (en) | Process for producing 3-(amidazo(1,2,a)benzimidazolyl-3)acryl acids | |
| CN118994180A (en) | Pranoprofen impurity and synthesis method and application thereof | |
| WO2005019229A1 (en) | Process for purification of boronic acid and its derivatives | |
| CN102690201A (en) | Simvastatin intermediate and preparation method thereof | |
| KR890002251B1 (en) | Method for preparing oxazole compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |